Product Description
SJX-653 is a novel neurokinin 3 receptor (NK3R) antagonist.
Mechanisms of Action: NK3 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sojournix
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Hot Flashes|Menopause
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04278872 |
SJX-653-006 | P2 |
Terminated |
Hot Flashes |
2021-02-12 |
29% |
2021-04-20 |
|
2019-002281-12 |
Effect of SJX-653 on Moderate to Severe Hot Flushes due to Menopause | P2 |
Unknown status |
Menopause |
2020-12-03 |
2022-03-13 |
Treatments |